Galactooligosaccharide Mixture for Lowering Cholesterol and Triglycerides

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for managing metabolic syndrome are inadequate in effectively reducing the risk of cardiovascular disorders and diabetes, as they often rely on lifestyle changes and medications that may not comprehensively address the underlying metabolic risk factors.

Innovation Solution

A composition comprising a mixture of galactooligosaccharides, specifically disaccharides, trisaccharides, tetrasaccharides, and pentasaccharides, which are fermented by colonic bacteria, is orally administered to lower cholesterol and triglyceride levels, thereby reducing the risk of metabolic syndrome and associated cardiovascular disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If lifestyle changes and medications are recommended to manage metabolic syndrome, then blood pressure, cholesterol and blood sugar levels are reduced, but the comprehensive effectiveness in reducing cardiovascular risk and diabetes risk remains inadequate

Engineering Contradiction:
Improveeffectiveness in reducing cardiovascular riskVSAvoidcomplexity of management approach
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent introduces galactooligosaccharides as an intermediary substance that mediates between dietary intake and metabolic health outcomes. These non-digestible carbohydrates act as prebiotics that selectively stimulate the growth of beneficial gut bacteria, which in turn produce metabolites that improve lipid profiles, reduce inflammation, and enhance insulin sensitivity, thereby comprehensively addressing multiple metabolic syndrome risk factors through a single dietary intervention

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If multiple medications are prescribed to reduce blood pressure, LDL cholesterol and blood sugar, then individual risk factors are addressed, but the overall risk reduction for heart disease and diabetes is insufficient

Engineering Contradiction:
Improverisk reduction outcomeVSAvoidsimplicity of intervention
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The patent applies the universality principle by demonstrating that galactooligosaccharides perform multiple therapeutic functions simultaneously: they lower total cholesterol and LDL cholesterol, reduce triglycerides, improve HDL cholesterol, reduce inflammatory markers, and enhance insulin sensitivity. This single prebiotic intervention universally addresses multiple metabolic syndrome components that would otherwise require multiple separate medications and lifestyle modifications

Inventive Principle:
Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The administration of this galactooligosaccharide mixture significantly increases beneficial gut bacteria, reduces inflammatory markers, and lowers insulin, cholesterol, and triglyceride levels, effectively mitigating the risk of metabolic syndrome and related cardiovascular issues.

Implementation Method 1

Galactooligosaccharides are non-digestible carbohydrates which are resistant to mammalian gastrointestinal digestive enzymes but are fermented by specific colonic bacteria

Methodology Applied
Scientific EffectFermentation: Fermentation

Data Source

PatentUS11052097B2Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome
Publication Date: 2021.07.06 CLASADO LTD

AI summary

The present invention relates to the use of a galactooligosaccharide composition for preventing or reducing the risk of developing metabolic syndrome.